Regeneron Pharmaceuticals Inc (REGN)vsRigel Pharmaceuticals Inc (RIGL)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
RIGL
Rigel Pharmaceuticals Inc
$26.29
+0.61%
HEALTHCARE · Cap: $489.54M
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 4774% more annual revenue ($14.34B vs $294.28M). RIGL leads profitability with a 124.7% profit margin vs 31.4%. RIGL trades at a lower P/E of 1.4x. RIGL earns a higher WallStSmart Score of 79/100 (B+).
REGN
Buy58
out of 100
Grade: C
RIGL
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Margin of Safety
+96.2%
Fair Value
$911.66
Current Price
$26.29
$885.37 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 125 of every $100 in revenue as profit
Strong operational efficiency at 33.2%
Revenue surging 21.2% year-over-year
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Smaller company, higher risk/reward
ROE of 1.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 124.7% and operating margin at 33.2%. Revenue growth of 21.2% demonstrates continued momentum.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, Return on Equity.
Key Dynamics to Monitor
REGN profiles as a value stock while RIGL is a growth play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.17 — expect wider price swings.
RIGL is growing revenue faster at 21.2% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
RIGL scores higher overall (79/100 vs 58/100), backed by strong 124.7% margins and 21.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?